| pubmed-article:8786464 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C0230445 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C0521457 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C0851346 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C0037633 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C1883073 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C0205431 | lld:lifeskim |
| pubmed-article:8786464 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
| pubmed-article:8786464 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8786464 | pubmed:dateCreated | 1996-9-25 | lld:pubmed |
| pubmed-article:8786464 | pubmed:abstractText | Benzoporphyrin derivative monoacid ring A (BPD-MA) is a second-generation photosensitizer for photodynamic therapy (PDT) that has shown good results in phase I clinical trials. Similar to other porphyrin derivatives, BPD-MA readily photobleaches during in-vivo PDT treatment. This study investigated the photodegradation of BPD-MA in fetal calf serum (FCS) solutions in vitro. Absorption and fluorescence spectra from dilute solutions of BPD-MA in 10% FCS were recorded before and immediately after irradiation with light at 694 nm. After irradiation, the appearance of a new fluorescence emission band at 650 nm and changes in the fluorescence excitation spectra indicate the formation of a photoproduct. Photoproduct formation was observed only when BPD-MA was bound to FCS and in oxygenated solutions. The spectroscopy of the photoproduct is consistent with the reaction of an oxygen species with the ring B vinyl group, forming a hydroxyaldehyde photoproduct. Monitoring the increase in photoproduct fluorescence during treatment may provide an in-vivo dosimeter to measure PDT efficacy. | lld:pubmed |
| pubmed-article:8786464 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8786464 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8786464 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8786464 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8786464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8786464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8786464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8786464 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8786464 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8786464 | pubmed:issn | 1011-1344 | lld:pubmed |
| pubmed-article:8786464 | pubmed:author | pubmed-author:DiddensHH | lld:pubmed |
| pubmed-article:8786464 | pubmed:author | pubmed-author:GilliesRR | lld:pubmed |
| pubmed-article:8786464 | pubmed:author | pubmed-author:HasanTT | lld:pubmed |
| pubmed-article:8786464 | pubmed:author | pubmed-author:KolliasNN | lld:pubmed |
| pubmed-article:8786464 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8786464 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:8786464 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8786464 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8786464 | pubmed:pagination | 87-90 | lld:pubmed |
| pubmed-article:8786464 | pubmed:dateRevised | 2007-7-23 | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:meshHeading | pubmed-meshheading:8786464-... | lld:pubmed |
| pubmed-article:8786464 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8786464 | pubmed:articleTitle | Spectral characterization of the benzoporphyrin derivative monoacid ring-A photoproduct formed in fetal calf solutions during irradiation with 694 nm continuous-wave radiation. | lld:pubmed |
| pubmed-article:8786464 | pubmed:affiliation | Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Boston, USA. | lld:pubmed |
| pubmed-article:8786464 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8786464 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:8786464 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
